Acting On Peptide Bonds (3.4) (e.g., Urokinease, Etc.) Patents (Class 424/94.63)
  • Patent number: 10897921
    Abstract: A method is disclosed for making palatable methionine-restricted foods, to deliver a methionine-restricted diet to human or veterinary patients. A protein or a food product containing protein is partially oxidized, preferably with ozone, to oxidize nearly all of the methionine and cysteine. After oxidation, tryptophan and lysine are optionally added back since they tend to be oxidized also. Optionally, a small amount of methionine is also added back so that the final methionine is within a preferred range of about 0.85 to about 1.8 gram methionine per 100 gram total protein, preferably about 1.2 gram per 100 gram total protein.
    Type: Grant
    Filed: June 4, 2014
    Date of Patent: January 26, 2021
    Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: John W. Finley, Thomas Gettys, Frank L. Greenway
  • Patent number: 10881717
    Abstract: The present disclosure relates to a method for increasing the stability of a Factor VIII molecule after purification, lyophilization and reconstitution, comprising preventing proteolytic cleavage of the Factor VIII molecule into a first fragment comprising essentially the A1 domain and the A2 domain and a second fragment comprising essentially the A3 domain, the C1 domain and the C2 domain throughout manufacturing the Factor VIII molecule. The disclosure further pertains to a method for improving the bioavailability of Factor VIII after intravenous and non-intravenous injection.
    Type: Grant
    Filed: December 3, 2019
    Date of Patent: January 5, 2021
    Assignee: CSL Limited
    Inventors: Carsten Horn, Sabine Zollner, Hubert Metzner, Stefan Schulte
  • Patent number: 10874721
    Abstract: The present invention relates to the use of plasminogen in the treatment of cervical erosion. Compared to other existing drugs for treating cervical erosion, the plasminogen or plasmin of the present invention can promote the inflammatory repair of damaged mucosa. Therefore, plasminogen may become a novel strategy to treat cervical erosion.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: December 29, 2020
    Assignee: Talengen International Limited
    Inventor: Jinan Li
  • Patent number: 10828276
    Abstract: Embodiments of the present invention are directed to the administration of bryostatins and bryostatins and retinoids for the treatment of disease responsive to increases in alpha secretase activity. Inventions of the present application are directed to the treatment of neuro-degenerative diseases such as Hutchinson Disease, Parkinson's disease, Down's syndrome and Alzheimer's disease and virus latency diseases such as HIV and Herpes, cancers such as prostate, melanomas, lymphomas and renal cancers, esophageal and opthalmic diseases such as glaucoma.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: November 10, 2020
    Inventor: Trevor Percival Castor
  • Patent number: 10744190
    Abstract: The present invention relates to a modified polypeptide comprising a non-cytotoxic protease, a translocation domain, a destructive protease cleavage site and a Targeting Moiety that binds to a Binding Site on a nerve cell, wherein after cleavage of the destructive cleavage site the polypeptide has reduced potency. The destructive cleavage site is recognised and cleaved by a protease present at or in an off-site target cell, and, in one embodiment, the polypeptide is a modified clostridial neurotoxin. The present invention also relates to the use of said polypeptides for treating a range of conditions, and to nucleic acids encoding said polypeptides.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: August 18, 2020
    Assignee: IPSEN BIOINNOVATION LIMITED
    Inventors: John Andrew Chaddock, Keith Alan Foster
  • Patent number: 10709771
    Abstract: The present invention relates to the effect of plasminogen in the prevention or treatment of retinopathy caused by diabetes mellitus, thereby providing a new therapeutic strategy for treating different types of diabetes mellitus-related retinopathy.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: July 14, 2020
    Assignee: TALENGEN INTERNATIONAL LIMITED
    Inventor: Jinan Li
  • Patent number: 10711178
    Abstract: A composition and a method to improve the exploit of oil from a hydrocarbon containing formation are disclosed. The method is characterized in that a aqueous composition including extract of a plant is injected into the formation to reduce the interfacial tension between the oil trapped in the formation and water, and the oil in said aqueous mixture is recovered for further use. Preferably, the aqueous mixture injected comprises an interfacial tension reducing composition made from a plant extract based on a plant family to which the plants Ziziphus Spina Christi and Aloe Vera belong. In particular the injection mixture also comprises at least one of the following constituents: fructose, sucrose, maltose, proteins, lipids and saponins.
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: July 14, 2020
    Assignee: Abu Dhabi University
    Inventor: Omar Chaalal
  • Patent number: 10648044
    Abstract: This document relates to molecular complexes having acid alpha glucosidase activity and at least one modification that results in enhanced ability of the molecular complex to be transported to the interior of a mammalian cell.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: May 12, 2020
    Assignee: Oxyrane UK Limited
    Inventors: Wouter Vervecken, Kathleen Camilla Telesphore Alida Maria Piens, Jan Robert Ludo Stout, Gwenda Noëlla Pynaert
  • Patent number: 10611799
    Abstract: An anti-endotoxin polypeptide is provided. The anti-endotoxin polypeptide having the formula (I) A1-L-C1, wherein A1 and C1 independently is a short peptide with ?-helix, L is AGP (Ala-Gly-Pro) or a peptide bond, and the hydrophobicity of the hydrophobic terminus in the anti-endotoxin polypeptide is between about 0.425 and 0.765. The anti-endotoxin polypeptide of the invention can neutralize the lipopolysaccharide and has the low hemolysis and high salt resistance, simultaneously. The present invention also provides a method for design an anti-endotoxin polypeptide, the anti-endotoxic activity is adjusted through increasing and/or decreasing hydrophobicity of the hydrophobic terminal end.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: April 7, 2020
    Assignee: NATIONAL TSING HUA UNIVERSITY
    Inventors: Jya-Wei Cheng, Hung-Lun Chu, Ya-Han Chih, Hui-Yuan Yu
  • Patent number: 10590402
    Abstract: Disclosed is a combination of two or more lipase enzymes, and its use for treating a lipid digestion deficiency and/or a digestive disorder. At least one lipase enzyme has a pH optimum at an acidic pH value, while at least one other lipase enzyme has a pH optimum at an alkalic pH value.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: March 17, 2020
    Assignee: CILIAN AG
    Inventors: Marcus Wolf William Hartmann, Ingo Aldag
  • Patent number: 10556037
    Abstract: The present invention is directed to topical enzymatic wound debriding compositions with enhanced enzymatic activity. These compositions comprise a dispersed phase comprising at least one proteolytic enzyme and at least one hydrophilic polyol; and a continuous phase comprising a hydrophobic base.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: February 11, 2020
    Assignee: Smith & Nephew, Inc.
    Inventors: Lei Shi, Aleksa Jovanovic, Duncan Aust
  • Patent number: 10550380
    Abstract: The present invention concerns a method for selectively activating a thermostable hydrolase at a temperature above T1. The present invention provides compositions comprising a thermostable hydrolase and a temperature sensitive inhibitor, wherein said thermostable hydrolase and said temperature sensitive inhibitor form a hydrolase-inhibitor complex at a temperature below T1, but which dissociates at a temperature of about T1. The present invention also relates to uses of said compositions, and a method for preparing said compositions.
    Type: Grant
    Filed: November 26, 2015
    Date of Patent: February 4, 2020
    Assignee: PURATOS NV
    Inventors: Geertrui Bosmans, Ellen Fierens, Kristof Brijs, Jan Delcour, Fabienne Verte, Jacques Georis, Valérie Dorgeo, Filip Arnaut
  • Patent number: 10544408
    Abstract: The present invention relates to a novel process of isolating and purifying tissue plasminogen activator and its variants more specifically TNK-tPA from CHO cells and describes an industrially applicable, simple, cost effective, robust and highly efficient process of TNK-tPA purification.
    Type: Grant
    Filed: October 19, 2015
    Date of Patent: January 28, 2020
    Assignee: GENNOVA BIOPHARMACEUTICALS LIMITED
    Inventors: Arjun Raghuwanshi, Shrawan Singh Kumar, Ankit Kumar, Mihir Sahoo Ranjan, Sanjay Singh
  • Patent number: 10450554
    Abstract: The present invention relates to a polypeptide having proline-specific endoprotease activity, selected from the group consisting of i. a polypeptide comprising a mature polypeptide sequence of SEQ ID NO: 2; ii. a polypeptide that has least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to the mature polypeptide sequence of SEQ ID NO: 2; iii. a polypeptide encoded by a nucleic acid that hybridizes under medium stringency, preferably under high stringency conditions to the complementary strand of the mature polypeptide coding sequence of SEQ ID NO:1; iv. a polypeptide encoded by a nucleic acid that has at least 70%, 75% 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to the mature polypeptide coding sequence of SEQ ID NO: 1. The invention further relates to a method of producing the polypeptide and a process for the preparation of a food or feed product wherein the polypeptide is used.
    Type: Grant
    Filed: May 19, 2015
    Date of Patent: October 22, 2019
    Assignee: DSM IP ASSETS B.V.
    Inventors: Jan Metske Van Der Laan, Peter Jozef Ida Van De Vondervoort, Chantal Christis, Martine Spaans, Angela De Bruine-Paulus, Johanna Henrica Gerdina Maria Mutsaers
  • Patent number: 10392609
    Abstract: Described herein are methods and genetically engineered cells useful for uncapping a mannose-6-phosphate residue on an oligosaccharide.
    Type: Grant
    Filed: November 14, 2016
    Date of Patent: August 27, 2019
    Assignees: Oxyrane UK Limited, VIB vzw, Universiteit Gent, Vrije Universiteit Brussel
    Inventors: Nico Luc Marc Callewaert, Wouter Vervecken, Petra Sophie Tiels, Han Karel Remaut, Kathleen Camilla Telesphore Alida Maria Piens
  • Patent number: 10370718
    Abstract: Provided herein are methods of adjusting or selecting a gluten peptide therapy based on the human leukocyte antigen (HLA) genotype, in particular HLA-DQ2.5 homozygosity, of a subject having or suspected of having Celiac disease. Also provided herein are methods of identifying (e.g., diagnosing) a subject, such as a subject having or suspected of having Celiac disease and/or assessing the efficacy of treatment of Celiac disease, e.g. by determining responsiveness to a therapeutic gluten peptide composition or cytokine response, and kits relating thereto.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: August 6, 2019
    Assignee: ImmusanT, Inc.
    Inventor: Robert P. Anderson
  • Patent number: 10344333
    Abstract: Systems, methods, and computer readable media for diagnosing or characterizing a genetic predisposition to develop cancer are provided. Nucleic acids comprising a germline nucleic acid sequence encoding the BRCA1 associated protein 1 are sequenced or probed to determine if the nucleic acid sequence includes alterations that predispose a subject to develop cancer.
    Type: Grant
    Filed: February 17, 2012
    Date of Patent: July 9, 2019
    Assignees: Institute For Cancer Research, University of Hawaii
    Inventors: Joseph R. Testa, Michele Carbone, Mitchell Cheung, Jianming Pei
  • Patent number: 10285922
    Abstract: An aqueous formulation for topical chemical exfoliation to the skin containing purified water, polyacrylic acid, disodium ethylenediaminetetraacetate, glycerin, specially denatured alcohol, dimethicone, cetyltrimethylammonium chloride, papain enzyme, citrus seed extract, and a nontoxic preservative. The formulation may further contain benzylalcohol and dehydroacetic acid which serve as effective nontoxic preservatives. The exfoliating formulations of the invention are useful in the removal of the surface layer of the skin and in particular, the dead cells of the stratum corneum. The formulation may be retained in an air tight vessel such as a syringe. About 5 rads to about 10 rads of gamma radiation may be applied to the formulation retained within the air tight vessel.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: May 14, 2019
    Inventor: Bruce Wayne Miller
  • Patent number: 10150803
    Abstract: The present invention relates a method of preparing a Glucagon-like peptide 2 (GLP-2) analog by gene recombination. The present invention provides an expression vector, which includes: (a) a nucleic acid sequence encoding tag protein; (b) a nucleic acid sequence encoding Smt3 protein (SEQ ID NO: 1); and (c) a nucleic acid sequence encoding linker peptide (SEQ ID NO: 2) and GLP-2 analog. The fusion protein expressed by the expression vector can be cleaved by thrombin, wherein the cleaving position is at the linker peptide, and then the GLP-2 analog is produced.
    Type: Grant
    Filed: January 17, 2017
    Date of Patent: December 11, 2018
    Assignee: CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO. LTD
    Inventors: Shih-Lin Chen, Ting-Yu Hsiung
  • Patent number: 10100296
    Abstract: The present invention provides compositions for use in the prophylaxis or treatment of a condition arising from gluten intolerance, the compositions including at least partially purified caricain (or a biologically active fragment, analog or variant thereof) alone or in combination with other suitable enzymes including bromelain, and/or an intestinal extract, as herein described. The present invention also provides methods of using such compositions for the prophylaxis or treatment of a condition arising from gluten intolerance.
    Type: Grant
    Filed: January 6, 2010
    Date of Patent: October 16, 2018
    Assignee: Glutagen Pty Ltd
    Inventors: Teodor Stelmasiak, Hugh James Beatty Cornell
  • Patent number: 9949489
    Abstract: Compositions having at least one compound which inhibits the formation of Hemipteran stylet sheaths and/or degrades hemipteran style sheaths that have already been formed, and thus deters or blocks hemipteran insects from feeding on plants, especially agriculturally important plants and methods of use of such compositions are described. Such compositions can be applied onto plants by spraying, dripping, or other methods and/or can be applied to the soil for uptake by the roots. These compositions and methods prevent and/or reduce the transmission of vascular associated diseases (caused by hemipteran vector-borne pathogens) to plants.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: April 24, 2018
    Assignee: The United States of America, as represented by the Secretary of Agriculture
    Inventors: Robert G. Shatters, Gary A. Luzio, John K. Morgan
  • Patent number: 9932569
    Abstract: Provided herein are antibacterial compositions and methods of making and using the compositions.
    Type: Grant
    Filed: February 21, 2017
    Date of Patent: April 3, 2018
    Assignee: GangaGen, Inc.
    Inventors: Chemira B Appaiah, Sriram Padmanabhan, R. Sanjeev Saravana, Bharathi Sriram
  • Patent number: 9907798
    Abstract: Methods of treating a head and neck cancer are disclosed.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: March 6, 2018
    Assignees: FOUNDATION MEDICINE, INC., UCL Business PLC
    Inventors: Chris Hendrik Boshoff, Timothy Robert Fenton, Matthias Alexander Lechner, Philip James Stephens, Matthew J. Hawryluk, Garrett Michael Frampton, Roman Yelensky
  • Patent number: 9901626
    Abstract: A method is disclosed to dissolve protein deposited in muscle. The method includes the step of administering an effective amount of an agent selected from the group consisting of fibrinolytics, proteolytics, photolytic and magnelytic agents.
    Type: Grant
    Filed: July 24, 2015
    Date of Patent: February 27, 2018
    Inventor: G. Blair Lamb
  • Patent number: 9879246
    Abstract: The present invention provides a fibrinolytic composition useful as a therapeutic for administration to a patient having a thrombotic occlusion. In one aspect of the present invention, the fibrinolytic composition comprises a reversibly inactivated acidified serine protease substantially free of a plasminogen activator, a low buffering capacity buffer, and optionally, a stabilizing agent. In another aspect of the invention, the fibrinolytic composition of the present invention comprises a reversibly inactivated acidified plasmin substantially free of a plasminogen activator, a low buffering capacity buffer, and optionally, a stabilizing agent.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: January 30, 2018
    Assignee: Grifols Therapeutics Inc.
    Inventors: Thomas P Zimmerman, Valery Novokhatny, Shan Jiang, James D Colandene
  • Patent number: 9850500
    Abstract: The present invention relates to a recombinant adenovirus capable of regulating angiogenesis, which comprises (a) an adenoviral UR (inverted terminal repeat) nucleotide sequence; and (b) a transcription regulatory sequence for a VEGF-A (vascular endothelial growth factor-A) gene comprising (i) a nucleotide sequence encoding a DNA binding domain comprising a zinc finger domain to bind to a site in a VEGF-A promoter sequence as set forth in nucleotides 1-2362 of SEQ ID NO:1, and (ii) a transcription activation domain or a transcription inhibitory domain linked to the nucleotide sequence encoding the DNA binding domain; and a pharmaceutical composition comprising the recombinant adenovirus.
    Type: Grant
    Filed: May 30, 2006
    Date of Patent: December 26, 2017
    Inventors: Chae-Ok Yun, Joo-Hang Kim, Jin Soo Kim, Hyun Chul Shin, Yoon A Kang
  • Patent number: 9797895
    Abstract: The present invention relates to the use of a composition comprising (a) at least three different amino acids, (b) at least two different amino acids and a saponin or (c) at least one dipeptide or tripeptide for stabilizing biomolecules immobilized on a solid carrier. The invention furthermore relates to a method for producing stabilized biomolecules, comprising embedding the biomolecules in the composition according to the invention and a method of producing a solid carrier having biomolecules attached thereto. The invention furthermore relates to a solid carrier producible or produced by the method of the invention and a method of diagnosing a disease using the carrier of the invention.
    Type: Grant
    Filed: March 31, 2010
    Date of Patent: October 24, 2017
    Assignee: Leukocare AG
    Inventors: Stefan Margraf, Anja Breuer, Martin Scholz, Jens Altrichter
  • Patent number: 9757433
    Abstract: The present invention relates to modified angiotensin converting enzyme 2 (ACE2) polypeptides and pharmaceutical and analytical uses thereof. In particular, the present invention relates to Zn2+ depleted-, Zn2+ free-, mixed metal- and metal ion substituted-ACE2 as well as methods for the manufacture of these variants and uses thereof, such as therapeutic and analytic uses of these ACE2 variants.
    Type: Grant
    Filed: January 13, 2014
    Date of Patent: September 12, 2017
    Assignee: Apeiron Biologicals AG
    Inventors: Hans Loibner, Bernhard Peball, Manfred Schuster, Stefan Stranner
  • Patent number: 9636385
    Abstract: Provided is a method of treatment for reducing fibrosis involving administering purified collagenase into an anterior chamber of an eye of a human patient.
    Type: Grant
    Filed: October 24, 2013
    Date of Patent: May 2, 2017
    Assignee: The Research Foundation for The State University of New York
    Inventor: Robert Honkanen
  • Patent number: 9611467
    Abstract: This invention relates to methods of subcutaneous administration of ADAMTS13 formulations to a treat a disease or condition associated with ADAMTS13 and VWF dysfunction. Furthermore, evidence of the unexpectedly high bioavailability of ADAMTS13 formulations administered subcutaneously is provided herein.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: April 4, 2017
    Assignees: BAXALTA GMBH, BAXALTA INCORPORATED
    Inventors: Alexandra Nathalie Kopic, Werner Höllriegl, Barbara Plaimauer, Hanspeter Rottensteiner, Eva-Maria Muchitsch
  • Patent number: 9605250
    Abstract: Provided herein are antibacterial compositions and methods of making and using the compositions.
    Type: Grant
    Filed: April 12, 2012
    Date of Patent: March 28, 2017
    Assignee: Gangagen, Inc.
    Inventors: Chemira B. Appaiah, Sriram Padmanabhan, R. Sanjeev Saravanan, Bharathi Sriram
  • Patent number: 9572866
    Abstract: Disclosed are polypeptides that are analogs of urocortin 2 that have pharmacological activity similar to urocortin 2 but have improved water solubility compared to urocortin 2, and pharmaceutical compositions of the polypeptides of the present invention. Also disclosed are polynucleotides encoding the polypeptides, and methods of treating pathophysiological states employing pharmaceutical compositions of the polypeptides and polynucleotides of the present invention. In addition, disclosed are vectors and host cells that include a nucleic acid encoding a polypeptide of the present invention, and kits that include pharmaceutical compositions of the present invention.
    Type: Grant
    Filed: July 17, 2015
    Date of Patent: February 21, 2017
    Assignee: Research Development Foundation
    Inventors: Wylie W. Vale, Jr., Joan M. Vaughan, Cindy Donaldson, Wolfgang Fischer, Jean E. F. Rivier
  • Patent number: 9517023
    Abstract: The invention provides methods for directing a localized biological response of a mammalian body to an implant disposed within the body. In one embodiment, a delivery system is positioned outside the body and adjacent to the implant within the body. The delivery system comprises a first tissue response modifier effective for directing a localized biological response of the body to the implant. The tissue response modifier is nonsurgically delivered from the delivery system into the body in a quantity effective to direct the localized biological response of the body to the implant. The invention also provides an implant system for long-term use comprising an implant and nonsurgical means for delivering a tissue response modifier through the epidermis of the body, the tissue response modifier effective for directing a localized biological response of the body to the implant.
    Type: Grant
    Filed: May 27, 2010
    Date of Patent: December 13, 2016
    Assignee: Profusa, Inc.
    Inventors: William A. McMillan, Natalie Wisniewski
  • Patent number: 9481713
    Abstract: The invention relates to a novel class of self-assembling peptides, compositions thereof, methods for the preparation thereof and methods of use thereof. The invention also encompasses methods for tissue regeneration, increasing the production of extracellular matrix proteins, and methods of treatment comprising administering self-assembling peptides.
    Type: Grant
    Filed: April 28, 2014
    Date of Patent: November 1, 2016
    Assignee: Massachusetts Institute of Technology
    Inventors: Yoshiyuki Kumada, Shuguang Zhang
  • Patent number: 9381243
    Abstract: The present invention relates to compounds for treatment that protects the endothelium, prevents pathologic thrombus formation in the microcirculation and preserves platelet number and function and thus may be related to minimizing or preventing development of organ failure, including multiple organ failure (MOF), and, hence, death in critically ill patients by administration of agent(s) limiting the platelets ability to aggregate and form clots and/or by agents modulating/preserving endothelial integrity and/or by agent(s) increasing the rate of thrombus lysis, and Another aspect of the invention related to by a cell-based whole blood viscoelastical haemostatic assay identifying critically ill patients at increased risk of development of organ failure, including multiple organ failure (MOF) and death.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: July 5, 2016
    Assignee: Rigshospitalet
    Inventors: Pär Johansson, Sisse Rye Ostrowski
  • Patent number: 9302027
    Abstract: A complex antimicrobial sorption composition possessing the necrolytic effect for treating the purulent wounds, the trophic ulcers, the wounds, and the infiltrates with the significant necrotic and exudative components represents the silica sorbent with the immobilized drug. Fine pyrogenic silica is used as a siliceous sorbent, and serrathiopeptidase as a drug.
    Type: Grant
    Filed: July 11, 2008
    Date of Patent: April 5, 2016
    Assignee: WILLINGSFORD LIMITED
    Inventors: Alexandr A. Golub, Olga O. Biliaieva, Viacheslav V. Neshta
  • Patent number: 9255295
    Abstract: The invention relates to a method for evaluating the sensitizing potential of a test compound, and to a kit for implementing said method.
    Type: Grant
    Filed: March 7, 2011
    Date of Patent: February 9, 2016
    Assignee: IMMUNOSEARCH
    Inventors: Hervé Groux, Françoise Cottrez
  • Patent number: 9180159
    Abstract: The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the protein kinase c-Jun amino terminal kinase, JNK inhibitor sequences, chimeric peptides, or of nucleic acids encoding same as well as pharmaceutical compositions containing same, for the treatment of non-chronic or chronic inflammatory digestive diseases, such as colitis, including e.g. Ulcerative colitis, Crohn's disease, diversion colitis, ischemic colitis, infectious colitis, fulminant colitis, chemical colitis, microscopic colitis, lymphocytic colitis, and atypical colitis, etc.
    Type: Grant
    Filed: June 2, 2009
    Date of Patent: November 10, 2015
    Assignee: Xigen Inflammation Ltd.
    Inventor: Christophe Bonny
  • Patent number: 9089150
    Abstract: The present invention provides a method for lowering the feed conversion rate in a vertebrate comprising inhibiting the function of secreted protein acidic and rich in cysteine (SPARC), wherein the feed conversion rate is defined as the mass of the feed eaten divided by the body mass gain.
    Type: Grant
    Filed: May 27, 2011
    Date of Patent: July 28, 2015
    Assignee: NATIONAL CHENG KUNG UNIVERSITY
    Inventors: Tzong-Yueh Chen, Yi-Ling Huang
  • Patent number: 9084748
    Abstract: Provided are a folyl extract of fermented soybean (EFS) produced by fermenting a culture including a folic acid and soybean extract by using a microorganism, and a composition including the folyl EFS. The folyl EFS has an anti-histamine effect, an anti-allergic effect, a calcium-absorption-promotion effect, a bone-growth-promotion effect, a cell growth promotion effect, a collagen biosynthesis promotion effect, a wrinkle improvement effect, and an UV-induced cell damage inhibition effect. Accordingly, the folyl EFS can be used in a skin external application or cosmetic composition, a health supplement food composition, a feed composition, and a pharmaceutical composition.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: July 21, 2015
    Assignees: Damy Chemical Co., Ltd.
    Inventors: Kwang Nyeon Kim, Boo Sun Cho
  • Patent number: 9066991
    Abstract: Improved matrix or hydrogel that is formed by enzymatic crosslinking of polymers wherein the crosslinking enzyme molecules have been modified for the purpose of improving the crosslinking density, mechanical properties, or other properties of the matrix, and/or to provide improved control over the rate and/or extent of crosslinking, wherein the enzyme molecules are modified to alter the perceived volume of the enzyme molecules in the crosslinked matrix being formed. Methods of production and of use are also provided.
    Type: Grant
    Filed: December 22, 2010
    Date of Patent: June 30, 2015
    Assignee: LIFEBOND LTD.
    Inventors: Orahn Preiss-Bloom, Guy Tomer
  • Patent number: 9056050
    Abstract: This invention relates to coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations. This invention further relates to methods of preparation and use of the systems, pharmaceutical compositions and preparations to treat persons having ADD, ADHD, autism, cystic fibrosis and other behavioral and neurological disorders.
    Type: Grant
    Filed: April 13, 2009
    Date of Patent: June 16, 2015
    Assignee: CUREMARK LLC
    Inventors: Joan Fallon, Matt Heil
  • Publication number: 20150147308
    Abstract: Described herein are compositions which include digestive enzymes and which are formulated to reduce one or more symptoms of a neuropsychiatric disorder. Also described herein is a method for treating an individual with a neuropsychiatric disorder using digestive enzymes and their derivatives to alleviate the symptoms of neuropsychiatric disorders. The method comprises administering to the individual an effective amount of digestive enzymes that are either naturally or recombinantly derived, or their derivatives, in an amount effective to reduce one or more symptoms of the neuropsychiatric disorder.
    Type: Application
    Filed: February 3, 2015
    Publication date: May 28, 2015
    Inventors: Joan M. Fallon, Matthew Heil, James Szigethy, James Fallon
  • Publication number: 20150132280
    Abstract: A human dietary supplement comprises theacrine and optionally other compounds that modulate the effects of theacrine. Uses for the theacrine-containing supplement include improvement of at least one of mood, energy, focus, concentration or sexual desire or a reduction of at least one of anxiety or fatigue.
    Type: Application
    Filed: November 12, 2014
    Publication date: May 14, 2015
    Applicant: ORTHO-NUTRA, LLC
    Inventors: Hector L Lopez, Shawn Wells, Tim N. Ziegenfuss
  • Patent number: 9023344
    Abstract: A therapeutic agent for the treatment of toxemia, preeclampsia and eclampsia and a method for preparing the therapeutic agent are disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or by other methods. Further, a method of using the presence of chymotrypsin in the maternal GI tract as a biomarker, to determine the likelihood of developing preeclampsia, a pregnancy induced hypertension, and eclampsia/toxemia is disclosed.
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: May 5, 2015
    Assignee: Curemark, LLC
    Inventor: Joan M. Fallon
  • Publication number: 20150118290
    Abstract: A method for reducing an established metastatic tumor, comprising administering an effective amount of a pharmaceutical composition to a subject in need, wherein the pharmaceutical composition comprises a polypeptide of a fibronectin-binding domain of dipeptidyl peptidase IV having a maltose-binding protein (MBP) fused at an N-terminal thereof, a cross-linking molecule, an active agent, and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: October 22, 2014
    Publication date: April 30, 2015
    Applicant: NATIONAL CHENG KUNG UNIVERSITY
    Inventors: HUNG-CHI CHENG, CHIEN-SHENG CHEN, YU-CHUAN LIN, CHIN-YUN CHENG, MING-MIN CHANG
  • Publication number: 20150118154
    Abstract: The present invention relates to methods for the treatment, the prognosis and the diagnosis of non-small cell lung cancer.
    Type: Application
    Filed: January 8, 2015
    Publication date: April 30, 2015
    Inventors: Marco Alifano, Patricia Forgez
  • Patent number: 9017667
    Abstract: The therapeutic efficacy of zymogen proteins for oral administration is improved by including in the formulation one or more excipients that optimize pH and other reaction conditions for rapid activation of the zymogen shortly after ingestion.
    Type: Grant
    Filed: October 9, 2009
    Date of Patent: April 28, 2015
    Assignee: Alvine Pharmaceuticals, Inc.
    Inventor: Bret Berner
  • Patent number: 9017665
    Abstract: A therapeutic agent for the treatment of the symptoms of addiction and the method for preparing the therapeutic agent is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using of a biomarker, the presence of chymotrypsin in the gastrointestinal tract to determine the presence of symptoms of addiction, and the likelihood of relapsing into addiction is disclosed.
    Type: Grant
    Filed: June 25, 2013
    Date of Patent: April 28, 2015
    Assignee: Curemark, LLC
    Inventor: Joan M. Fallon
  • Patent number: 8980254
    Abstract: Pharmaceutical formulations of orally administered proteins can be stabilized from oxidative degradation and inactivation in the stomach and GI tract by the addition of an antioxidant.
    Type: Grant
    Filed: August 21, 2009
    Date of Patent: March 17, 2015
    Assignee: Alvine Pharmaceuticals, Inc.
    Inventors: Matthew John Siegel, Bret Berner